You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD1 antibody

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1

Active, not recruiting
  • Gastric or Gastroesophageal Junction Adenocarcinoma
  • neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Jul 4, 2023

Stage IIIA Hepatocellular Carcinoma Trial (Radiotherapy combined with TKI and Anti-PD-1 Antibody)

Not yet recruiting
  • Stage IIIA Hepatocellular Carcinoma
  • Radiotherapy combined with TKI and Anti-PD-1 Antibody
  • (no location specified)
Sep 24, 2023

PD-1 Antibody, Hemophagocytic Lymphohistiocytosis, Epstein-Barr Virus Trial in Beijing (L-DEP and PD-1 antibody)

Not yet recruiting
  • PD-1 Antibody
  • +3 more
  • L-DEP and PD-1 antibody
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Mar 8, 2023

Solid Tumor, Adult, Relapsed Cancer, Refractory Cancer Trial (HST-1011, Cemiplimab)

Not yet recruiting
  • Solid Tumor, Adult
  • +2 more
  • (no location specified)
Dec 14, 2022

Anti-PD-1 Antibody Plus Regorafenib in Refractory Microsatellite

Completed
  • Metastatic Colorectal Adenocarcinoma
  • regorafenib plus anti-PD-1 antibodies
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 4, 2023

Colorectal Cancer Stage II, Colorectal Cancer Stage III, Mmr Deficiency Trial in Guangzhou (drug, radiation, procedure, other)

Active, not recruiting
  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III
  • Guangzhou, Guangdong, China
    Medical Oncology,Sun Yat-sen University Cancer Center
Jan 29, 2023

Transarterial Therapies+Donafenib + Anti-PD-1 Antibody for uHCC:

Not yet recruiting
  • Hepatocellular Carcinoma Non-resectable
  • transarterial therapies
  • (no location specified)
Nov 27, 2022

Neoadjuvant Chemo, PD-1 Antibody, Radiotherapy Trial (neoadjuvant chemo combined with PD-1 antibody + radical radiotherapy)

Not yet recruiting
  • Neoadjuvant Chemotherapy
  • +3 more
  • neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy
  • (no location specified)
Sep 21, 2022

Sarcoma Trial in Shanghai (MASCT-I,PD1 Antibody,Apatinib)

Active, not recruiting
  • Sarcoma
  • MASCT-I,PD1 Antibody,Apatinib
  • Shanghai, Shanghai, China
    Shanghai Sixth People's Hospital
Nov 22, 2022

Esophageal Squamous Cell Carcinoma Abdominal Stage 0 Trial in Guangzhou (PD-1 Inhibitors, Irinotecan, Capecitabine tablets)

Recruiting
  • Esophageal Squamous Cell Carcinoma Abdominal Stage 0
  • PD-1 Inhibitors
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 20, 2023

Unresectable Intrahepatic Cholangiocarcinoma Trial (Camrelizumab, Gemcitabine Injection, Cisplatin injection)

Not yet recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • (no location specified)
Feb 17, 2023

Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin

Recruiting
  • Gastric Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Solid Tumor, Adult, EphA2 Overexpression, KRAS G12V Trial in Beijing (KRAS-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +4 more
  • KRAS-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Leptomeningeal Disease Trial in Germany (Nivolumab [Opdivo])

Recruiting
  • Leptomeningeal Disease
  • Nivolumab [Opdivo]
  • Freiburg, Germany
  • +6 more
Nov 2, 2022

Hepatocellular Carcinoma Trial in Beijing (Sintilimab, Lenvatinib, radiotherapy)

Recruiting
  • Hepatocellular Carcinoma
  • Beijing, Beijing, China
    Beijing Tsinghua Changgung Hospital
Jan 5, 2023

Solid Tumor, Adult, Lymphoma, EphA2 Overexpression Trial in Beijing (TP53-EphA-2-CAR-DC, Abraxane, Cyclophosphamide)

Recruiting
  • Solid Tumor, Adult
  • +6 more
  • TP53-EphA-2-CAR-DC
  • +3 more
  • Beijing, Beijing, China
    Biotherapeutic Department of Chinsese PLA Gereral Hospital
Nov 29, 2022

Locally Advanced Unresectable or Metastatic Esophageal Cancer Trial (Futibatinib, Pembrolizumab, Cisplatin)

Not yet recruiting
  • Locally Advanced Unresectable or Metastatic Esophageal Cancer
  • (no location specified)
Jul 6, 2023

Basal Cell Carcinoma Trial in Zürich (Cemiplimab Injection [Libtayo])

Recruiting
  • Basal Cell Carcinoma
  • Cemiplimab Injection [Libtayo]
  • Zürich, Switzerland
    University Hospital Zurich, Clinic of Dermatology
Nov 3, 2022

Cholangiocarcinoma, Intrahepatic Trial in Shanghai (Capecitabine, PD-1 Antibody(Tislelizumab))

Recruiting
  • Cholangiocarcinoma, Intrahepatic
  • Shanghai, China
    Lulu@Huashan.Org.Cn
Aug 16, 2022

NSCLC Trial in Zhengzhou (L-TIL, Tislelizumab, Docetaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • L-TIL, Tislelizumab, Docetaxel
  • Zhengzhou, Henan, China
    No.127 Dongming Road
May 17, 2023

Sintilimab in Combination With Chemoradiotherapy in High-risk

Recruiting
  • Nasopharyngeal Carcinoma
  • Sintilimab
  • Sintilimab (PD-1 Antibody)
  • Nanning, Guangxi, China
    Guangxi Medical University Cancer Hospital
Jan 29, 2023

Melanoma Trial in Beijing (KD6001, Toripalimab)

Not yet recruiting
  • Melanoma
  • Beijing, China
    Beijing Cancer Hospital
Feb 3, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Immune Function and PD-1 Antibody Therapy Efficacy Predictors on

Recruiting
  • Secondary Hemophagocytic Lymphohistiocytosis
  • Chronic Active Epstein-Barr Virus Infection
  • No intervention
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
May 2, 2023

NSCLC Trial in China (PD-1 Antibody, BACE)

Recruiting
  • NSCLC
  • PD-1 Antibody
  • BACE
  • Guiyang, Guizhou, China
  • +7 more
Nov 8, 2022